Chlorhexidine

Generic Name: Chlorhexidine

Brand Names: Betasept, Hibiclens, Instillagel, Nupro Chlorhexidine, Oris, Oro-Clense, Paroex, Perichlor, Peridex, Periochip, Periogard, Prevora, X-pur

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₀Cl_₂N_₁₀

CAS Number: 55-56-1

Unique Ingredient Identifier: R4KO0DY52L

Background: Chlorhexidine is a broad-spectrum antimicrobial biguanide used as a topical antiseptic and in dental practice for the treatment of inflammatory dental conditions caused by microorganisms. It is one of the most common skin and mucous membrane antiseptic agents in use today. The molecule itself is a cationic bis-guanide consisting of two 4-chlorophenyl rings and two biguanide groups joined by a central hexamethylene chain. Topical chlorhexidine for disinfection, as well as oral rinses for dental use, carries activity against a broad range of pathogens including bacteria, yeasts, and viruses.

Chlorhexidine was developed in the UK by Imperial Chemical Industries in the early 1950s and was introduced to the US in the 1970s. The FDA withdrew its approval for the use of chlorhexidine gluconate topical tincture 0.5%, due to a significant number of reports concerning chemical and thermal burns associated with the use of this product. Other formulations of chlorhexidine continue to be available.

Indication: Chlorhexidine is available over-the-counter in various formulations (e.g. solution, sponge, cloth, swab) as a topical antiseptic to sanitize prior to surgeries and/or medical procedures. Dental formulations, available by prescription only, include an oral rinse indicated for the treatment of gingivitis and a slow-release "chip" which is inserted into periodontal pockets and is indicated for the reduction of pocket depth in adult patients with periodontitis as an adjunct therapy to dental scaling and root planing procedures.

Associated Conditions: Aphthous ulcer, Catarrh of the throat, Chemotherapy Induced Oral Mucositis, Chronic Wounds, Decubitus Ulcer, Dental Cavity, Dysphagia, Eczema infected, Foeter Ex Ore, Gingival Bleeding, Gingival Diseases, Gingivitis, Glossitis, Hoarseness, Infection, Infectious Periodontal Diseases, Injury Throat, Mild to Moderate Inflammatory Reaction of the Oral Cavity, Mild to Moderate Inflammatory Reaction of the Pharynx, Mouth injury, Mucositis, Neurodermatitis, Ocular Inflammation, Ocular Irritation, Oral Aphthous Ulcer, Pain, Periodontitis, Pharyngitis, Plaque, Dental, Postoperative Wound Infection, Purulent Gingivitis, Radiation Mucositis, Red eye, Ringworm, Skin Infections, Sore Throat, Stomatitis, Surgical Wounds, Tissue Damage, Tonsillitis, Ulcers, Leg, Wound Infections, Bacterial skin infections, Dry, cracked skin, Gum pain, Moderate Gingivitis, Oral infections, Oral lesions, Recurrent Oral fungal infection, Severe Gingivitis, Superficial Wounds, Throat disinfection, Tongue inflammation

Associated Therapies: Anesthesia of Mucous Membrane, Antimicrobial Therapy, Contact Lens Care, Disinfection, Disinfection of External Genitalia, Disinfection of the Urethra, Disinfection of the Vaginal Mucosa, Irrigation therapy, Lubrication of the Urethra, Oral Care, Oral Hygiene, Oropharyngeal antisepsis, Promotion of wound healing, Skin disinfection, Surgical Scrubbing, Topical Antisepsis, Urethral Anesthesia, Wound Cleansing, Oral antisepsis, Oral disinfection

Clinical Trials

Evaluations of the Effects of Tranexamic Acid and Chlorhexidine Gel on Alveolar Osteitis Incidence

Not Applicable

Active, not recruiting

Conditions: Alveolar Osteitis

Interventions: Drug: Absorbable Gelatin
Drug: Tranexamic acid
Drug: Chlorhexidine

First Posted Date: 2024-05-30

Last Posted Date: 2024-05-30

Lead Sponsor: Recep Tayyip Erdogan University

Target Recruit Count: 98

Registration Number: NCT06435832

Locations: 🇹🇷
Recep Tayyip Erdoğan University, Rize, Turkey

Comparisons Of Different Antiplaque Agents On Gingivitis In Orthodontic Patients

Not Applicable

Completed

Conditions: Gingivitis

Interventions: Drug: Placebo
Drug: combination gel (chlorhexidine and metronidazole)
Drug: Chlorhexidine Gluconate
Drug: Metronidazole

First Posted Date: 2024-03-12

Last Posted Date: 2024-03-13

Lead Sponsor: Anam Sattar

Target Recruit Count: 80

Registration Number: NCT06305546

Locations: 🇵🇰
Dow University of Health Sciences, Karachi, Sindh, Pakistan

The Effect of Smoking and Chlorhexidine on Periodontal Tissues After Non- Surgical Periodontal Therapy in Patients With Periodontitis

Not Applicable

Active, not recruiting

Conditions: Periodontal Diseases
Smoking
Periodontitis

Interventions: Procedure: non surgical periodontal therapy
Drug: Chlorhexidine mouthwash

First Posted Date: 2024-01-05

Last Posted Date: 2024-01-05

Lead Sponsor: University of Rijeka

Target Recruit Count: 60

Registration Number: NCT06191497

Locations: 🇭🇷
Faculty of dental medicine, Rijeka, Croatia

A Pilot Observation and Feasibility Study of Prevora, Integrated Into Homecare Visits of High-risk Adults

Not yet recruiting

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
CHF (Congestive Heart Failure)
Dialysis
Chronic Metabolic Disorder

Interventions: Drug: Prevora

First Posted Date: 2023-12-06

Last Posted Date: 2023-12-06

Lead Sponsor: CHX Technologies Inc.

Target Recruit Count: 30

Registration Number: NCT06158633

Chlorhexidine Gel Versus Alvogyl Following Surgical Extraction of Impacted Mandibular Third Molar

Phase 4

Completed

Conditions: Impacted Third Molar Tooth

Interventions: Drug: Alvogyl
Drug: Chlorhexidine Gluconate

First Posted Date: 2023-11-22

Last Posted Date: 2023-11-22

Lead Sponsor: University of Baghdad

Target Recruit Count: 51

Registration Number: NCT06144983

Locations: 🇮🇶
University of Baghdad, Baghdad, Iraq

Infection Prophylaxis in Total Joint Replacement

Phase 3

Recruiting

Conditions: Periprosthetic Joint Infection

Interventions: Other: Saline
Other: Povidone-Iodine
Drug: Vancomycin Hydrochloride
Drug: Chlorhexidine Gluconate

First Posted Date: 2023-11-13

Last Posted Date: 2024-08-21

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 21006

Registration Number: NCT06126614

Locations: 🇨🇦
Hamilton Health Sciences - Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Phase 2

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Amivantamab IV
Drug: Amivantamab SC
Drug: Lazertinib
Drug: Doxycycline
Drug: Minocycline
Drug: Clindamycin
Drug: Chlorhexidine
Other: Noncomedogenic skin moisturizer
Other: Ruxolitinib
Other: Tacrolimus

First Posted Date: 2023-11-07

Last Posted Date: 2025-04-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 300

Registration Number: NCT06120140

Locations: 🇹🇷
Adana City Hospital, Adana, Turkey
🇹🇷
Gulhane Training and Research Hospital, Ankara, Turkey
🇨🇳
Sichuan Cancer Hospital, Chengdu, China

and more 90 locations